BACKGROUND AND PURPOSE: Immunization with heat shock proteins, gp96, elicits specific protective immunity against parent tumors. However, it is marginally effective as a therapeutic tool against established tumors. In the present study, we evaluated the efficacy and mechanism of immunotherapy with bone marrow-derived dendritic cells (DCs) pulsed with tumor-derived gp96 against murine lung cancer. METHODS: Mice were transplanted subcutaneously with ovalbumin (OVA)-transfected Lewis Lung Cancer (LLC-OVA) cells and immunized with gp96 derived from LLC-OVA, DCs, or DCs pulsed with gp96 derived from LLC-OVA. RESULTS: The antitumor effect was significantly enhanced in the mice immunized with DCs pulsed with gp96 derived from LLC-OVA, compared to mice immunized with gp96 or DCs (P<0.05). The antitumor effect was significantly dependent on natural killer (NK) cells and CD8(+) cells and partially dependent on CD4(+) cells. Analysis by laser confocal microscopy demonstrated that gp96 was shown on the cell surface at 15 min, and after 30 min internalized in the endosomes and not in the endoplasmic reticulum or lysosomes. OVA-specific(+) CD8(+) cells were more readily recruited into the draining lymph nodes and higher CD8(+) cytotoxic T cell activity against LLC-OVA was observed in splenocytes from mice immunized with DCs pulsed with gp96 derived from LLC-OVA. Re-challenge of the surviving mice with LLC-OVA tumors after the initial tumor inoculation showed dramatic retardation in tumor growth. CONCLUSION: In conclusion, immunotherapy of DCs pulsed with tumor-derived gp96 against murine lung cancer is effective through immune response of CD8(+) cytotoxic T lymphocytes and NK cells.
BACKGROUND AND PURPOSE: Immunization with heat shock proteins, gp96, elicits specific protective immunity against parent tumors. However, it is marginally effective as a therapeutic tool against established tumors. In the present study, we evaluated the efficacy and mechanism of immunotherapy with bone marrow-derived dendritic cells (DCs) pulsed with tumor-derived gp96 against murinelung cancer. METHODS:Mice were transplanted subcutaneously with ovalbumin (OVA)-transfected Lewis Lung Cancer (LLC-OVA) cells and immunized with gp96 derived from LLC-OVA, DCs, or DCs pulsed with gp96 derived from LLC-OVA. RESULTS: The antitumor effect was significantly enhanced in the mice immunized with DCs pulsed with gp96 derived from LLC-OVA, compared to mice immunized with gp96 or DCs (P<0.05). The antitumor effect was significantly dependent on natural killer (NK) cells and CD8(+) cells and partially dependent on CD4(+) cells. Analysis by laser confocal microscopy demonstrated that gp96 was shown on the cell surface at 15 min, and after 30 min internalized in the endosomes and not in the endoplasmic reticulum or lysosomes. OVA-specific(+) CD8(+) cells were more readily recruited into the draining lymph nodes and higher CD8(+) cytotoxic T cell activity against LLC-OVA was observed in splenocytes from mice immunized with DCs pulsed with gp96 derived from LLC-OVA. Re-challenge of the surviving mice with LLC-OVA tumors after the initial tumor inoculation showed dramatic retardation in tumor growth. CONCLUSION: In conclusion, immunotherapy of DCs pulsed with tumor-derived gp96 against murinelung cancer is effective through immune response of CD8(+) cytotoxic T lymphocytes and NK cells.
Authors: Alexandra K Fraik; Mark J Margres; Brendan Epstein; Soraia Barbosa; Menna Jones; Sarah Hendricks; Barbara Schönfeld; Amanda R Stahlke; Anne Veillet; Rodrigo Hamede; Hamish McCallum; Elisa Lopez-Contreras; Samantha J Kallinen; Paul A Hohenlohe; Joanna L Kelley; Andrew Storfer Journal: Evolution Date: 2020-06-03 Impact factor: 3.694
Authors: Ephraim A Ansa-Addo; Jessica Thaxton; Feng Hong; Bill X Wu; Yongliang Zhang; Caroline W Fugle; Alessandra Metelli; Brian Riesenberg; Katelyn Williams; Daniel T Gewirth; Gabriela Chiosis; Bei Liu; Zihai Li Journal: Curr Top Med Chem Date: 2016 Impact factor: 3.295
Authors: Cesar Tovar; Amanda L Patchett; Vitna Kim; Richard Wilson; Jocelyn Darby; A Bruce Lyons; Gregory M Woods Journal: PLoS One Date: 2018-04-27 Impact factor: 3.240